Insider Buying: Charles River Laboratories International, Inc. (NYSE:CRL) COO Buys 1,514 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) COO Birgit Girshick purchased 1,514 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $163.11 on Monday. The business’s 50 day simple moving average is $172.84 and its 200-day simple moving average is $188.00. The firm has a market capitalization of $8.34 billion, a price-to-earnings ratio of 1,087.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company’s quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.46 EPS. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CRL shares. Morgan Stanley dropped their price target on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. UBS Group restated a “neutral” rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Bank of America dropped their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a report on Monday, November 18th. Finally, Evercore ISI lifted their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $195.71.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Mackenzie Financial Corp raised its holdings in Charles River Laboratories International by 0.6% in the 4th quarter. Mackenzie Financial Corp now owns 977,073 shares of the medical research company’s stock valued at $180,368,000 after acquiring an additional 5,805 shares during the last quarter. Forum Financial Management LP raised its holdings in Charles River Laboratories International by 30.3% in the 4th quarter. Forum Financial Management LP now owns 1,565 shares of the medical research company’s stock valued at $289,000 after acquiring an additional 364 shares during the last quarter. Montchanin Asset Management LLC acquired a new position in Charles River Laboratories International in the 4th quarter valued at $258,000. GF Fund Management CO. LTD. acquired a new position in Charles River Laboratories International in the 4th quarter valued at $227,000. Finally, GTS Securities LLC raised its holdings in Charles River Laboratories International by 33.1% in the 4th quarter. GTS Securities LLC now owns 2,151 shares of the medical research company’s stock valued at $397,000 after acquiring an additional 535 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).